Vimarsana
Biggest News Aggregation in the World

Prophase Labs News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Prophase Labs. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Prophase Labs Today - Breaking & Trending Today

Contrasting ProPhase Labs (NASDAQ:PRPH) and Panbela Therapeutics (NASDAQ:PBLA) - Vimarsana News

Contrasting ProPhase Labs (NASDAQ:PRPH) and Panbela Therapeutics (NASDAQ:PBLA)

ProPhase Labs (NASDAQ:PRPH – Get Free Report) and Panbela Therapeutics (NASDAQ:PBLA – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, valuation, institutional ownership, dividends, risk and analyst recommendations. Profitability This table compares ProPhase Labs and […]

ProPhase Labs (NASDAQ:PRPH) Share Price Passes Above Two Hundred Day Moving Average of $5.08 - Vimarsana News

ProPhase Labs (NASDAQ:PRPH) Share Price Passes Above Two Hundred Day Moving Average of $5.08

ProPhase Labs, Inc. (NASDAQ:PRPH – Get Free Report)’s stock price crossed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $5.08 and traded as high as $5.26. ProPhase Labs shares last traded at $5.24, with a volume of 24,833 shares traded. Analysts […]

ProPhase Labs, Inc. (NASDAQ:PRPH) to Post Q1 2025 Earnings of $0.10 Per Share, Diamond Equity Forecasts - Vimarsana News

ProPhase Labs, Inc. (NASDAQ:PRPH) to Post Q1 2025 Earnings of $0.10 Per Share, Diamond Equity Forecasts

ProPhase Labs, Inc. (NASDAQ:PRPH – Free Report) – Diamond Equity issued their Q1 2025 EPS estimates for shares of ProPhase Labs in a note issued to investors on Monday, April 22nd. Diamond Equity analyst H. Diamond forecasts that the company will post earnings per share of $0.10 for the quarter. The consensus estimate for ProPhase […]

Source: wkrb13.com
Baystreet.ca - ProPhase Flat on Cancer Drug Progress - Vimarsana News

Baystreet.ca - ProPhase Flat on Cancer Drug Progress

ProPhase Labs, Inc. (NASDAQ: PRPH) saw its shares lose some strength Wednesday, as the next-generation biotech, genomics, and diagnostics company, reported its progress on the commercialization of its breakthrough BE-Smart test for esophageal cancer. ...

ProPhase Labs (NASDAQ:PRPH) Receives Buy Rating from HC Wainwright - Vimarsana News

ProPhase Labs (NASDAQ:PRPH) Receives Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of ProPhase Labs (NASDAQ:PRPH – Free Report) in a research note released on Wednesday morning, Benzinga reports. HC Wainwright currently has a $11.00 target price on the stock. ProPhase Labs Price Performance PRPH stock opened at $4.96 on Wednesday. The company has a fifty day moving average […]